Christian BOREL

De Azevedo, J., Mourtada, J., Bour, C., Devignot, V., Schultz, P., Borel, C., Pencreach, E., Mellitzer, G., Gaiddon, C., & Jung, A. C. (2022). The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells, 11(18), 2866. https://doi.org/10.3390/cells11182866

Borel, C., Regnier-Gavier, O., Carinato, H., Guihard, S., Antoni, D., Demarchi, M., Sirlin, F., Exinger, D., Petit-Jean, E., Thiery, A., Bronner, G., Schultz, P., Flesch, H., Frasie, V., Prébay, D., Petit, T., Jung, A. C., Burgy, M., & Coliat, P. (2018). Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. Oncotarget, 9(101), 37581–37588. https://doi.org/10.18632/oncotarget.26506

Jégu, J., Belot, A., Borel, C., Daubisse-Marliac, L., Trétarre, B., Ganry, O., Guizard, A.-V., Bara, S., Troussard, X., Bouvier, V., Woronoff, A.-S., Colonna, M., & Velten, M. (2015). Effect of previous history of cancer on survival of patients with a second cancer of the head and neck. Oral Oncology, 51(5), 457–463. https://doi.org/10.1016/j.oraloncology.2015.01.010

Jégu, J., Binder-Foucard, F., Borel, C., & Velten, M. (2013). Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncology, 49(1), 9–14. https://doi.org/10.1016/j.oraloncology.2012.06.018

Le Tourneau, C., Jung, G.-M., Borel, C., Bronner, G., Flesch, H., & Velten, M. (2008). Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Oto-Laryngologica, 128(6), 706–712. https://doi.org/10.1080/00016480701675668

Le Tourneau, C., Velten, M., Jung, G.-M., Bronner, G., Flesch, H., & Borel, C. (2005). Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head & Neck, 27(9), 801–808. https://doi.org/10.1002/hed.20254

Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J.-F., Borel, C., Mors, R., Haegelé, P., Eber, M., & Ghnassia, J.-P. (2004). Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. European Journal of Cancer (Oxford, England: 1990), 40(2), 205–211.

Cutuli, B., Borel, C., Dhermain, F., Magrini, S. M., Wasserman, T. H., Bogart, J. A., Provencio, M., de Lafontan, B., de la Rochefordiere, A., Cellai, E., Graic, Y., Kerbrat, P., Alzieu, C., Teissier, E., Dilhuydy, J. M., Mignotte, H., & Velten, M. (2001). Breast cancer occurred after treatment for Hodgkin’s disease: analysis of 133 cases. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 59(3), 247–255.

Petit, T., Georges, C., Jung, G. M., Borel, C., Bronner, G., Flesch, H., Massard, G., Velten, M., Haegele, P., & Schraub, S. (2001). Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 12(5), 643–646.

Cutuli, B., Dhermain, F., Borel, C., de Larochefordiere, A., Graic, Y., de Lafontan, B., Dilhyudy, J. M., Mignotte, H., Tessier, E., Tortochaux, J., N’Guyen, T., Bey, P., Le Mevel-Le Pourhiet, A., Velten, M., & Arriagada, R. (1997). Breast cancer in patients treated for Hodgkin’s disease: clinical and pathological analysis of 76 cases in 63 patients. European Journal of Cancer (Oxford, England: 1990), 33(14), 2315–2320.